Pharmacy Times

JULY 22, 2025

This change mirrored a January 2025 FDA safety alert and label update that urged providers to consider genetic testing, inform patients of the risks, and discuss available options. 5 In the biopharmaceutical industry, pharmacogenetics is increasingly employed to stratify patient populations and identify responders during drug development.

Pharmacy Technician 20

Pharmacy Technician Insurance Coverage and Processing Compounding Pharmacies Diabetes 20

Pharmacy Times

JULY 2, 2025

Common adverse reactions included gastrointestinal issues, with a low discontinuation rate due to adverse drug reactions. 2,4 The open-label, single-arm, multicenter, multidose study enrolled 86 patients with CKD and hyperphosphatemia receiving maintenance hemodialysis.

Pharmacy Technician 29

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunity 29

Pharmacy Times

JUNE 12, 2025

3 The safety profile was favorable with the most common adverse effect (AE) being increased creatinine, increased potassium, dysuria, decreased hemoglobin, increased aspartate aminotransferase, increased alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infection, decreased neutrophils, and hematuria.

Pharmacy Technician 26

Pharmacy Technician Compounding Pharmacies Biosimilars Pharmacy Management 26

Pharmacy Times

JULY 9, 2025

The FDA has approved an updated label with a new recommended titration dosing schedule for donanemab-azbt (Kisunla; Eli Lilly and Company) for once-monthly amyloid-targeting therapy for adults that experience early symptomatic Alzheimer disease (AD). million individuals in the United States aged 65 and older.

Labelling 26

Labelling Pharmacy Technician Compounding Pharmacies Independent Pharmacies 26